Before being discontinued, the P2X7 receptor blocker had cleared a master protocol study in chronic pain, though Eli Lilly ...

In a recent study, researchers have uncovered significant differences in how medical laboratories interpret diagnostic results for Lyme disease, underscoring the urgent need for harmonized standards ...

Trials-in-progress poster of ongoing pivotal Phase 3 trial of DNA-mediated immunotherapy accepted at both IGCS and ESMO Congress ...

CHICAGO -- Plaque psoriasis drug deucravacitinib (Sotyktu) now looks likely to win a psoriatic arthritis (PsA) indication in ...

Icotrokinra demonstrated clinically meaningful outcomes at Week 28 in the Phase 2b ANTHEM-UC study in ulcerative colitis, with 31.7% of patients achieving clinical remission and 38.1% showing endoscop ...

IMNN-001 program is currently advancing its OVATION 3 pivotal Phase 3 trial per plan. LAWRENCEVILLE, N.J., Oct. 23, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinica ...

After 23 years of follow-up, the European Randomized Study of Screening for Prostate Cancer (ERSPC) confirmed a 13% lower ...

James Chelnis, MD, FACS, is an ophthalmic plastic and reconstructive surgeon at Manhattan Face & Eye. At the 2025 American ...

Central Asia’s diet is characterized by a heavy reliance on red meat, bread, and dairy, staples that are often missing or ...

Highlights New analysis of ATH434-201 double blind trial strengthens efficacy signal at high dose levelPositive data from ATH434-202 open-label ...

Illume Fertility, a leading fertility practice in the tri-state area known for its award-winning medical team of expert physicians, patient-centered care, and advanced reproductive treatments enabling ...

Confluent is positioning itself as the "context layer for enterprise AI" with new capabilities that aim to solve the problem ...